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ABSTRACT Group A Streptococcus (GAS) genotype emm89 is increasingly recognized as a leading cause of disease worldwide, yet
factors that underlie the success of this emm type are unknown. Surveillance identified a sustained nationwide increase in
emm89 invasive GAS disease in the United Kingdom, prompting longitudinal investigation of this genotype. Whole-genome se-
quencing revealed a recent dramatic shift in the emm89 population with the emergence of a new clade that increased to domi-
nance over previous emm89 variants. Temporal analysis indicated that the clade arose in the early 1990s but abruptly increased
in prevalence in 2008, coinciding with an increased incidence of emm89 infections. Although standard variable typing regions
(emm subtype, tee type, sof type, andmultilocus sequence typing [MLST]) remained unchanged, uniquely the emergent clade
had undergone six distinct regions of homologous recombination across the genome compared to the rest of the sequenced
emm89 population. Two of these regions affected known virulence factors, the hyaluronic acid capsule and the toxins NADase
and streptolysin O. Unexpectedly, and in contrast to the rest of the sequenced emm89 population, the emergent clade-associated
strains were genetically acapsular, rendering them unable to produce the hyaluronic acid capsule. The emergent clade-associated
strains had also acquired an NADase/streptolysin O locus nearly identical to that found in emm12 andmodern emm1 strains but
different from the rest of the sequenced emm89 population. The emergent clade-associated strains had enhanced expression of
NADase and streptolysin O. The genome remodeling in the new clade variant and the resultant altered phenotype appear to have
conferred a selective advantage over other emm89 variants andmay explain the changes observed in emm89 GAS epidemiology.
IMPORTANCE Sudden upsurges or epidemic waves are common features of group A streptococcal disease. Although the mecha-
nisms behind such changes are largely unknown, they are often associated with an expansion of a single genotype within the
population. Using whole-genome sequencing, we investigated a nationwide increase in invasive disease caused by the genotype
emm89 in the United Kingdom.We identified a new clade variant that had recently emerged in the emm89 population after hav-
ing undergone several core genomic recombination-related changes, two of which affected known virulence factors. An unusual
finding of the new variant was the loss of the hyaluronic acid capsule, previously thought to be essential for causing invasive dis-
ease. A further genomic adaptation in the NADase/streptolysin O locus resulted in enhanced production of these toxins.
Recombination-related genome remodeling is clearly an important mechanism in group A Streptococcus that can give rise to
more successful and potentially more pathogenic variants.
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The human pathogen Streptococcus pyogenes or group A Strep-tococcus (GAS) accounts for over 600 million infections glob-
ally per year with a high level of morbidity and mortality (1).
Frequently observed upsurges in GAS disease are associated with
the emergence and expansion of a new emm genotype or the sud-
den increase of a preexisting common emm type. Themechanisms
behind such epidemic waves of disease are largely unknown but
may in part be due to the transference of new virulence factors
between strains,mediated bymobile genetic elements such as bac-
teriophages commonly found in the GAS population.
Recent epidemiological evidence points to a rapid emergence
of the GAS genotype emm89 as a leading cause of disease in the
United Kingdom and other parts of the world, particularly Can-
ada (2). Indeed, globally, emm89 is nowamong the topfive leading
emm types, equally capable of causing both invasive and noninva-
sive disease (2–13), as well as outbreaks (14–16). We identified a
sustained rise in invasive GAS (iGAS) disease caused by emm89
strains in the United Kingdom over the past decade. Indeed,
emm89 strains have remained among the top three emm types
causing iGAS and occasionally have even overtaken the consis-
tently dominant emm1. Despite the global prevalence of emm89, it
is a relatively understudied emm type. Here, we report the first
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genomic study of emm89 GAS and reveal the emergence of a new
emm89 clade variant that had undergone homologous recombi-
nation of core genomic regions. The new emergent clade variant
was unexpectedly genetically acapsular and exhibited enhanced
production of the toxins NADase and streptolysin O (SLO). Fur-
thermore, the emergent acapsular clade variant increased in the
population, temporally associated with the rise in emm89 iGAS,
and is now the dominant emm89 variant in the United Kingdom
population.
RESULTS
An increase in emm89 iGAS. National surveillance of iGAS in
England and Wales, supported by serological and then molecular
typing of iGAS-associated strains, identified a sustained increase
in disease caused by strains of the emm89 lineage from 1998 to
2013. While the rise in emm89 strains between 1999 and 2005 was
broadly in proportion with the overall rise in iGAS infection, a
disproportionate rise was evident from 2005 to 2009; emm89 case
numbers increased 2.6-fold compared to 1.8-fold for all other
emm types combined (Fig. 1A). The proportion of all iGAS infec-
tions due to emm89 increased from 10% in 2005 to 18% in 2007.
Between 2003 and 2013, 7-day and 30-day case fatality rates attrib-
utable to emm89 iGAS disease were 14% and 21%, respectively;
while year-to-year fluctuation in case fatality rates was observed,
there were no significant temporal trends (Fig. 1B).
A high level of single nucleotide polymorphisms (SNPs) de-
fines anovel clade of emm89GAS.The sustained increase in prev-
alence of emm89 iGAS coupled with the lack of emm89-specific
genomic information regarding emm89 virulence provided the
rationale for whole-genome sequencing (WGS) of 131 emm89
clinical GAS strains. Sequenced strains included 9 to 11 emm89
isolates from each year 2004 to 2013 comprising similar numbers
of invasive (58/131) and noninvasive (73/131) isolates, randomly
selected from those submitted to the national reference laboratory
fromdifferent locations throughout theUnited Kingdom (see Ta-
ble S1 in the supplemental material). To provide a reference
emm89 genome for comparative analysis, one clinical necrotizing
fasciitis isolate, H293, was sequenced to completion and anno-
tated (GenBank accession no. HG316453.2).
Mapping of the short read sequences generated fromWGS for
all 130 additional emm89 isolates to the completedH293 reference
genome identified 2,075 single nucleotide polymorphisms
(SNPs). Surprisingly, an SNP-based phylogenetic reconstruction
revealed a separate clade of isolates within the emm89 population,
distinct from isolates that clustered close to the reference strain
H293 (Fig. 2A). Invasive and noninvasive GAS infection isolates
were equally represented across the phylogeny. The clade was
characterized by 229 SNPs, shared by all members of the clade
compared to all other sequenced emm89 strains.Within the clade,
there were additional polymorphisms; pairwise analysis of clade-
associated strains showed that they differed by an average of 80
SNPs, while, outside the clade, strains differed by an average of 57
SNPs. Strain H1041 appeared to be a potential hypermutator
strain with 223 SNPs compared to the reference strain, 180 of
which were unique to this strain (Fig. 2A).
Sequence typing information was extracted from de novo as-
semblies of the WGS isolates but identified no clade-associated
differences; all 131 strainswere emm subtype emm89.0,multilocus
sequence type 101, serum opacity factor type sof89, and T-antigen
gene type tee11. Analysis for SNP clustering and sites of potential
recombination revealed that the genomic distribution of the 229
SNPs characterizing the clade was not even (see Fig. S1 in the
supplemental material). The majority of SNPs (202, 88%) clus-
tered into six distinct regions (regions 1 to 6), located around the
chromosomal origin of replication (Fig. 2B). These regions were
within the core genome and unassociated with any potential mo-
bile genetic elements. Within regions 1 to 6, the ratio of nonsyn-
onymous to synonymous SNPs (dN/dS) was ~0.3, yet outside
these regions the dN/dS ratio was ~1.8. The higher proportion of
synonymous to nonsynonymousmutations within the six regions
is consistent with recombination and indicates diverged donor
lineages (17).
Evolution of emm89 GAS in United Kingdom population.
Temporal investigation of the emm89 population structure by
genomic and phylogenetic analysis revealed a dramatic national
shift. The core SNP phylogeny, excluding all regions of recombi-
nation, indicated that the United Kingdom had hosted a diverse
emm89 population, fromwhich a distinct clade emerged (Fig. 2C).
By 2008, the emergent clade had increased in the population and
became dominant over any previous United Kingdom emm89
variant (Fig. 3). To investigate the population dynamics of emm89
strains, we performed temporal Bayesian analyses (BEAST) using
SNPs identified in the core genome, excluding regions of pre-
dicted recombination. This revealed that the time to most recent
common ancestor (tMRCA) of the whole emm89 population was
FIG 1 United Kingdom epidemiology of emm89 invasive GAS disease
(iGAS). (A) Incidence of emm89 iGAS (black solid line, left axis) alongside the
total numbers of iGAS cases of all emm types (gray dotted line, right axis). (B)
Thirty-day case fatality rates of emm89 iGAS (95% confidence interval).
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approximately 1970 (2May 1970; 95% highest probability density
[HPD], 22 December 1962 to 7 July 1977) (see Fig. S2A in the
supplemental material). The estimated substitution rate for the
populationwas 7.99 107 site1 year1 (95%HPD, 6.58 107
to 9.35 to 107 site1 year1), corresponding to an evolutionary
rate of 2.1 SNPs per genome per year, similar to rates determined
for other GAS emm types (18, 19). Linear regression of maximum
likelihood root-to-tip distances against the year of sampling
showed a strong correlation with these data (see Fig. S2B). Using
the Bayesian phylogenetic reconstruction, we were able to esti-
mate that the tMRCA of the emergent clade was approximately
1992 (22 June 1992; 95% HPD, 13 August 1988 to 10 June 1996).
FIG 2 Phylogenetic analysis of all 131 emm89 isolates sequenced. (A) Maximum likelihood unrooted tree based on core SNPs compared to the reference strain
H293. Eighty-three of 131 isolates clustered into a distinct emergent clade (circled) separate from the 47/131 isolates that clustered with the reference strainH293
(indicated by asterisk). A potential hypermutator strain, H1041, is indicated by a red branch. (B) Schematic of the H293 genome. The outer ring indicates the
positions of the six regions of recombination present in emergent clade-associated emm89 strains relative to H293 and all other non-clade-associated emm89
strains (regions 1 to 6 shown in red). The inner two rings represent GC skew and GC content. (C) Mid-rooted phylogenetic tree based on core genome SNPs
compared to the reference strainH293 excluding all regions of predicted recombination. The emergent emm89 clade is distinct from the rest of the diverse emm89
population. Strains are color coded by year of isolation. The presence of each of the 11 different superantigen genes is indicated to the right of the tree.
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Based on the phylogenetic framework and the temporal cali-
bration, it would appear that the six recombination regions
which are uniquely present in the emergent clade were ac-
quired at some point in the ~20-year period prior to its emer-
gence, i.e., between the tMRCA of the emergent clade and the
last ancestral node shared with the rest of the population (7
September 1973; 95% HPD, 30 May 1967 to 28 July 1980). We
predict that the recombination occurred in a step-by-step pro-
cess due to the relatively dispersed location of the regions on
the chromosome; however, we have not been able to identify
any intermediate strains that have fewer than the six regions of
recombination present, possibly because they have been lost in
the population. Since the emergence of the new clade in the
early 1990s, the population has expanded to become the dom-
inant emm89 subclone.
Prophage-like element with superantigen gene speC associ-
ated with majority of emergent clade-associated strains. The
genomic complement of up to 11 known streptococcal superan-
tigen genes can be variable as, with the exception of speJ, speG, and
smeZ, superantigen genes are associated with potentially mobile
bacteriophages. Notably, however, 71/83 strains of the emergent
clade carried speC (86%) compared to only 10/48 strains outside
this clade (21%) (Fig. 2C). All 71/83 speC-positive clade-
associated strains carried the same prophage-like element with
speC and a DNase gene, spd1, commonly found associated with
speC. This prophage-like element was not found in any strains
outside the clade; strains outside the clade with speC carried the
toxin gene on a different prophage, of which there have been sev-
eral identified for GAS. The emergent clade-associated speC-spd1
prophage-like element (named M89.1) was similar to that
found in M1 GAS strain SF370 (370.1) (Fig. 4); however, the
predicted phage structural genes from370.1 (20) were absent in
M89.1, suggesting that M89.1 cannot form a lysogenic phage
particle. WhileM89.1 was common among the emergent clade-
associated strains, the phage was not universally present and did
not characterize the clade.
Phenotypic impact of recombination-related remodeling.
Wehypothesized that recombination-related genome remodeling
led to the emergence of the new emm89 clade variant and provided
a selective advantage over previous emm89 variants through al-
tered phenotype and/or enhanced pathogenesis. The SNPs pres-
ent in regions 1, 3, 4, and 5 (Table 1) were unlikely to result in any
phenotypic changes as the few, if any, nonsynonymous SNPs pres-
ent in these regions were predicted not to affect protein structure
or function. Two regions, however, affected knownGAS virulence
factors: the NADase/streptolysin O toxin locus (region 2) and the
hyaluronic acid (HA) capsule locus (region 6).
Genomic region 2: effects on NADase locus/streptolysin O.
The gene nga encodes NADase, a secreted toxin that cleaves
-NAD, an essential component of many energy-producing re-
actions. NADase enters host cells through pores made by the co-
expressed streptolysin O, encoded by slo; thus, they work in com-
bination to produce a toxic effect on host cells (21, 22). Compared
to all non-clade-associated emm89 strains, the emergent clade-
associated strains contained 17 SNPswithin nga, six of whichwere
nonsynonymous, and 23 SNPs in slo, eight of which were nonsyn-
onymous. All sequenced emm89 strains were predicted to have a
functional NADase and SLO despite the SNPs within coding re-
gions (23–25). Remarkably, although all clade-associated strains
tested were capable of hydrolyzing NAD, only two non-clade-
associated strains tested had detectable NADase activity (Fig. 5A).
A Western blotting assay probing for NADase indicated that this
difference in activity was accounted for by enhanced protein ex-
pression of NADase by clade-associated strains (see Fig. S3 in the
supplemental material).
Similar toNADase, all emergent clade-associated strains tested
demonstrated high activity of SLO (Fig. 5B) in contrast to non-
clade-associated strains tested, only two of which had SLO activ-
ity. Some emergent clade-associated strains tested (HM11,HM61,
H636, H637, and H657) demonstrated enhanced NADase and
FIG 3 Rise of the emergent clade to dominance in the United Kingdom
emm89 population. Between 2004 and 2007, the United Kingdom was repre-
sented by a diverse emm89 population (blue line, left axis); however, there was
a sudden switch between 2007 and 2008 and the emergent clade-associated
emm89 variant (red line, left axis) became the dominating type in the popula-
tion. The rise of the emergent clade coincidedwith an increase in the frequency
of emm89 iGAS in the United Kingdom (gray dotted line, right axis). Associ-
ation with the emergent clade was determined by WGS of 126 emm89 strains
(excluding pairs of strains isolated from the same patient) isolated in 2004 to
2013 (n 10 for 2005, 2006, 2007, 2011, and 2013; n 11 for 2004 and 2008;
n 28 for 2009; n 17 for 2010; n 9 for 2012).
FIG 4 Prophage-like element found in the emergent clade-associated strains. In clade-associated strains, the superantigen gene speC (shown in red) and the
DNase gene spd1 (shown in orange) were associated with a prophage-like element (M89.1) that shared a high level of identity to a prophage found in the
genome of M1 strain SF370 (370.1). Bacteriophage structural genes found in370.1 (20) are absent inM89.1. The figure was drawn using Easyfig (52).
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SLO activity that could possibly be related to mutations in the
regulatory kinase gene, covS. The two-component system CovR/S
is known to negatively regulate the expression of the nga/ifs/slo
locus, which in turn is modulated by the regulator of cov, rocA,
which influences covR/S regulation (26, 27). Interestingly, the SLO
and NADase activity of the two unusual non-clade-associated
strains could also be potentially due to a mutation in covS and a
deletion of the rocA gene in strains H395 and H543, respectively.
TABLE 1 Genes located within recombination regions 1 to 6 and associated single nucleotide polymorphismsa
Region Gene Function
No. of mutations
AA change(s)S NS
Total/total
in region
1 pbpb1b Penicillin binding
protein
7 2 9/23 Ile430Val,
Val537Ile
rpoB DNA-directed
RNA polymerase
14 0 14/23
2 00183 Hypothetical
protein
1 2 3/130 Arg3Iso,
Ala67Val
purA Adenylosuccinate
synthetase
45 5 50/130 Gly84Ala,
Thr213Ala,
Leu348Phe,
Lys351Glu,
Tyr355His
00185 Nucleoside-binding
protein
5 1 6/130 Ala332Thr
nusG Transcription
antitermination
protein
3 0 3/130
nga NAD glycohydrolase 11 6 17/130 Ala99Val,
His103Arg,
Arg136Gly,
His143Gln,
Met221Iso,
Gln253His
ifs Immunity factor
for SPN/NGA
2 2 4/130 Gly7Ser,
Ala136Val
slo Streptolysin O 15 8 23/130 Thr39Ala,
Iso59Thr,
Ala130Thr,
Met172Arg,
Asp182Asn,
Asp324Glu,
Thr450Ser,
Arg470Gln
metB Cystathionine
beta-lyase
2 1 3/130 Val241Ala
3 00285 D-Alanyl-D-alanine
carboxypeptidase
6 2 8/9 Iso27Met,
Tyr364Gln
dacA.1 D-Alanyl-D-alanine
carboxypeptidase
1 0 1/9
4 lacR.2 Lactose phosphotransferase
system repressor
9 0 9/16
5 01551 ABC transporter
ATP-binding protein
5 0 5/9
01552 ABC transporter 2 2 4/9 Asp269Gly,
Asp408Gly
6 01673 Zn-dependent
peptidase
1 1 2/15 Iso169Val
01677 Hypothetical protein 1 3 4/15 Thr67Iso,
Iso83Met,
Gln115Lys
recF DNA replication
and repair protein
4 4 8/15 Ala59Glu,
Gln246His,
Asn263Asp,
Val363Iso
a Abbreviations: S, synonymous; NS, nonsynonymous; AA, amino acid (position in relation to reference H293 strain).
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The virulence of globally dominant modern emm1 strains has
been attributed to the acquisition of a 36-kb genomic region pos-
sibly from emm12 strains that includes the nga-slo locus and led to
subsequent enhancement of SLO and NADase expression (19,
25). A comparison of the emm89 nga-slo locus (and surrounding
12-kb sequence SPYH293_0083 tometB) with all sequenced GAS
genomes available demonstrated that the sequence in clade-
associated emm89 strains shares 99% DNA identity with that of
modern emm/M1 strains and emm/M12 strains (see Fig. S4 in the
supplemental material). Whether this reflects recombination be-
tween emm89 and emm1 or emm89 and emm12 GAS is unclear,
but recombination has resulted in a potentially advantageous in-
crease in NADase/SLO production by the emergent clade-
associated strains that recapitulates the production observed with
modern emm/M1 strains (19, 25).
Genomic region 6: effects on the synthesis of the hyaluronic
acid capsule. Region 6 contained five genes, three of which are
required for synthesis of the hyaluronic acid (HA) capsule: hasA,
hasB, and hasC. In the emergent clade-associated strains, the en-
tire hasABC locus, including the promoter region, was completely
absent and in place of this locus was a short region of 157 bp in
length. The 157-bp sequence was not found anywhere else in the
emm89 genome or in any other sequenced GAS genomes except
for MGAS10750, an M4 strain that also lacks the hasABC locus
(28). Interestingly, the same 157-bp sequence is also present in the
completed genomes of Streptococcus dysgalactiae subsp. equisimilis
in what appears to be a homologous region (see Fig. S5 in the
supplemental material).
HA production was measured using an enzyme-linked immu-
nosorbent assay (ELISA)-based assay specific for HA. No HA was
detected in strains that were members of the emergent clade, i.e.,
negative for the HA capsule locus hasABC, as expected (Fig. 5C).
Strains outside the emergent clade all produced clearly detectable,
albeit variable, levels of HA.
TheHAcapsule has been shown to be a critical virulence factor,
particularly in the resistance of different emm-type GAS strains to
phagocytosis (29–35). Surprisingly, given the differences in the
capsule phenotypes of clade-associated and non-clade-associated
FIG 5 Variation in phenotype between emm89 strains. (A) NADase activities of 34 sequenced emm89 strains were measured in the culture supernatant; the
result shown is the highest 2-fold dilution able to hydrolyze NAD. Data represent the median (plus range) from four independent experiments. (B) SLO
activities of 34 sequenced emm89 strains weremeasured in the culture supernatant by lysis of sheep erythrocytes and reported as the percentage of activity relative
to the positive control (H2O). Data represent the means ( standard deviations) from three independent experiments. (C) Production of hyaluronic acid was
measured using an ELISA-based assay for hyaluronan. Representatives of the non-clade-associated emm89 strains tested all had detectable levels of hyaluronic
acid. All representatives of emergent clade-associated strains tested had undetectable levels of hyaluronic acid (N.D., not detected). Data represent themeans (
standard deviations) from three independent experiments. Hyaluronic acid capsule was measured as femtograms per 1  103 CFU. (D) Both non-clade-
associated and clade-associated emm89 strains survive equally well in whole human blood. There was no overall difference in multiplication factor between the
two types of strains, including (as shown) or excluding (not shown) strains with covR/S or rocAmutations. Strains were grown in duplicate using a single donor,
and data represent the means. The experiment was repeated in a second donor with similar results. (E) The ability of invasive non-clade-associated strains (n
23) and emergent clade-associated strains (n 21) to adhere to and colonize uncoated plastic after 24 h of culture was measured by staining with Gram’s crystal
violet. Data represent the means from three experiments. **, P  0.01, Mann-Whitney comparison. Strains with blue bars or unfilled circles (non-clade-
associated emm89 strains) and red bars or unfilled squares (emergent clade-associated emm89 strains) carry mutations in covR/S or rocA known to control
expression of nga, slo, and hyaluronic acid capsule; mutations in either covR/S or rocA would enhance nga, slo, and capsule expression.
Turner et al.
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strains, all strains were equally able to survive and multiply in
whole human blood (Fig. 5D).
We hypothesized that the emergent clade-associated strains
might demonstrate enhanced persistence, related to loss of cap-
sule and increased exposure of streptococcal surface binding pro-
teins. To test this, the ability of both clade-associated and non-
clade-associated strains to adhere to and colonize plastic was
measured. On uncoated plastic, the emergent clade-associated
strains were significantly better able to adhere and colonize than
non-clade-associated strains (Fig. 5E), confirming that the emer-
gent clade had acquired a phenotype that may be advantageous to
environmental transmission or persistence.
DISCUSSION
The rise of emm89 iGAS in the United Kingdom coincided with
the emergence and increased prevalence of a variant acapsular
clade that differed from the rest of the emm89 population by six
regions of core genome homologous recombination, providing
the first direct evidence of multiple dynamic changes in the GAS
core genome within a single emm type. Of these genomic regions,
two were most notable: first, the absence of the hasABC locus,
resulting in nonencapsulation, and, second, changes in the nga-slo
locus with enhanced expression of these toxins. We hypothesize
that the genome remodeling that occurred in the emergent clade
variant provided a selective advantage that allowed it to outcom-
pete other emm89 variants.
A high level of variation can occur within specific emm-type
populations, but this is usually attributed to mobile genetic
element-mediated DNA transfer such as bacteriophages or inte-
grative conjugative elements (ICEs). The recombination events
leading to the emergence of the new clade variant appeared to be
through core genome homologous recombination, not associated
with mobile genetic elements, the mechanism for which is not
understood in naturally untransformable bacteria such as GAS
(36). It is possible that the emergent clade-associated strains ac-
quired heightened ability to recombine compared with other
emm89 strains, potentially through the loss of capsule allowing
enhanced exogenous DNAuptake or some other unknownmech-
anism arising from core genomic changes. The close proximity of
SNPswithin each region suggests that single recombination events
occurred at each site, although the mechanism behind the recom-
bination events is uncertain, and two or more sites may have re-
combined in a single event. A lower dN/dS ratio was observed
within regions of recombination compared to the rest of the ge-
nome, indicating diverged donor lineages already selectively
purged of deleterious mutations (17). The donor(s) may have
been another GAS strain of a different emm type or possibly even
another streptococcal species such as S. dysgalactiae subsp. equisi-
milis. Genetic exchange between GAS and S. dysgalactiae subsp.
equisimilis has been previously described, although prophage or
ICE mediated (37). Interestingly, although separated by ~53 to
129 kb from each other, the six regions are located within 239 to
261 kb of the origin of replication. The origin of replication as a
hot spot for homologous recombination has been observed for
other bacteria, possibly due to an increase in DNA copy number
surrounding the origin during replication and exponential growth
(36, 38).
The genome remodeling that led to emergence of the new clade
had a substantial impact on two virulence factor loci with clear
phenotypic consequences. Although the phenotypic changes ob-
served appear significant, we cannot exclude other factors that
may have aided the success of the new clade variant, including
potential subtle effects from one or more of the other regions of
recombination or SNPs located elsewhere in the genome. Outside
the six regions of recombination, 27 SNPswere shared by all clade-
associated strains compared to all non-clade-associated strains
(see Table S2 in the supplemental material). Eighteen of 27 of
these SNPs were nonsynonymous changes, and 14 were predicted
to affect protein structure and/or function (as predicted by SIFT
Blink [39]).We could not determine any obvious negative or pos-
itive impact that these SNPs may have on pathogenicity, based on
predicted functions of the proteins, although we cannot exclude a
role, and further work is required to determine any possible con-
tribution to the emergence of the new clade. Notably, there was
evidence for selection outside the six regions of recombination:
three clade-associated SNPs were found in parE (two of which
were nonsynonymous) and two clade-associated SNPs were
found in pstA (one nonsynonymous). While these genes were not
predicted to be areas of recombination by Gubbins analysis, and
neither encodes known virulence factors, a role in pathogenesis
remains possible. We predict that, together with the regions of
recombination identified, there are likely to be additional changes
contributing to the success of the emergent clade in the emm89
population.
The absence of the HA capsule locus in the emergent clade
variant emm89 was unexpected and distinct from any dynamic
change previously reported in GAS. The HA capsule was believed
to be required by other serotypes for full pathogenesis. The ability
of acapsular emm89 to survive and indeed outcompete related
encapsulated strains, along with the recent recognition that emm4
and emm22 strains are also acapsular (28), suggests that encapsu-
lation is not as essential for pathogenesis by all strains as previ-
ously thought and may even provide an advantage. Whether
acapsular status represents an adaptation to altered environment
or host response is unknown, but so far, emm89 is the only emm
type to include both capsular and acapsular genotypes. We do not
know if the MRCA of the emm89 population was genetically cap-
sular or acapsular; hence, it is unclear as to whether the emergent
clade variant became acapsular through recombination with
emm4, emm22, or even S. dysgalactiae subsp. equisimilis or
whether other non-clade-associated strains became capsular
through recombination with other encapsulated emm types.
TheBayesian analyses and root-to-tip correlation converged to
estimate that the acapsular genotype/phenotype of emm89 has
been in the population since at least the early 1990s, but the rise to
domination was a more recent event, which was associated with a
sudden increase in the incidence of iGAS. Although surprising, we
do not know if the length of time between emergence and increase
to dominance of this variant over other emm89 variants is atypical.
Transmission rates and spread of GAS clones within the host pop-
ulation are not well understood, and work such as this has been
limited so far. Acquisition of additional SNPs and/or the speC/
spd1-associated prophage M89.1 may have also contributed to
the sudden increase of the acapsular clade variant within the pop-
ulation. Unknown host factors influencing the bacterial popula-
tion should also not be excluded. It will be interesting to continue
to monitor the emm89 population and expand the study globally.
Prevalence of noninvasive GAS infection is not subject to rig-
orous national surveillance; thus, we cannot rule out a specific
association with invasive disease, although this seems unlikely as
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genomic differences were found in both invasive and noninvasive
strains. There was also no indication of enhanced severity associ-
atedwith invasive disease caused by the emergent clade-associated
isolates, as indicated by 7- and 30-day case fatality rates. We hy-
pothesize that the genomic changes acquired by clade-associated
strains may have favored mucosal or fomite adherence and trans-
mission, affecting the quantity rather than severity of invasive dis-
ease. This is supported by the observation that clade-associated
strains demonstrated an enhanced ability to adhere to plastic
compared with non-clade-associated strains.
During throat carriage, GAS can undergo inactivating muta-
tions in the capsule locus that prevent capsule synthesis, but loss of
capsule promotes both adhesion to epithelium and internaliza-
tion into host pharyngeal cells (40). Such strains, however, lack
virulence and are poorly able to survive in whole human blood,
remaining fixed in a colonization state unable to cause invasive
disease. In contrast, acapsular emm89 clade-associated GAS
strains have acquired potential for long-term colonization
through complete loss of capsule but manifestly retain the ability
to cause invasive disease. Thus, long-term-colonized individuals
may carry and transmit the emergent clade-associated emm89
strains capable of causing invasive disease. The acapsular nature of
the emergent clade-associated strains and increased expression of
SLO and NADase will enhance internalization and intracellular
bacterial survival in epithelial cells, theoretically providing protec-
tion fromnatural antimicrobial peptides and antibiotic treatment.
The acquisition of a 36-kb genomic region that includes the
nga-slo locus, possibly fromM12, with enhanced toxin expression
is thought to be responsible for the emergence and subsequent
rapid global spread of M1T1 (19, 25). This mirrors our observa-
tion of the emergence of acapsular clade-associated emm89 as a
leading cause of disease that had acquired a similar nga-slo locus as
part of a 12-kb region of recombination (region 2). This region
appears variable across several different emm types, and it is un-
clear at this stage whether enhanced nga-slo toxin production is
due to a single or several polymorphisms within the nga-slo locus
and promoter or a combination of multiple factors present in the
surrounding 12-kb region and/or the entire genome.
Within the emergent clade-associated strains, we also identi-
fied a phage-like element,M89.1, associated with two other vir-
ulence factors, a superantigen encoded by speC and a DNase en-
coded by spd1, whichmay also contribute to disease pathogenesis.
M89.1 was not, however, a ubiquitous feature of the emergent
clade variant. Some non-clade-associated emm89 strains also car-
ried speC and spd1, although they were associated with other
prophages that can be found in other emm types of GAS. The
presence of other superantigen genes, speA, speK, speL, speM, and
ssa, varied between all emm89 strains attributable to the varying
distribution of other mobile GAS prophages.
Although this was a United Kingdom-based study, emm89
GAS is increasing in prevalence worldwide (2, 6, 9, 12). Whether
clade shift is occurring globally is as yet unclear, although we have
identified at least one clade-associated genotype strain from Ge-
neva, Switzerland. Standard molecular typing methods failed to
distinguish the emergent acapsular clade variant from the previ-
ous emm89 population, though PCR-based surveillance (as de-
tailed in Fig. S6 in the supplementalmaterial) will allow continued
enhanced surveillance of this important clade shift. emm89 GAS
strains are widely considered to be capable of causing both skin
and throat infections (41), as members of the so-called emm pat-
tern group “E,” a grouping system related to the chromosomal
organization of emm subfamily genes. The differences observed in
the current study occurred without any change in emm gene or-
ganization and may affect patterns of GAS persistence and car-
riage in humans or, potentially, in the environment. The findings
underline the need to reassess the population risks posed by hu-
man infection or environmental contamination by nonencapsu-
lated GAS strains and support further investigation of potential
sources of transmission based on circulating strain types.
MATERIALS AND METHODS
Epidemiology. Epidemiological data were extracted from all invasive in-
fections reported to the Public Health England reference laboratory from
the United Kingdom between 1994 and 2013 which were associated with
invasive (sterile-site) isolates. Prior to 1999, emm/M89 was designated
PT4245 (42), and these infections were also included. Seven- and 30-day
case fatality rates were obtained where data were available; prior to 2003,
data could not be obtained accurately and so were excluded from the
analysis. Patient vital status was derived from the Demographic Batch
Service.
Bacterial strains. Thirty invasive and noninvasive emm89 GAS iso-
lates from Imperial College Healthcare NHS Trust, West London, were
cultured and stored between 1995 and 2011 (see Table S1 in the supple-
mental material). One hundred one additional emm89 isolates were ob-
tained from strains submitted to the national reference laboratory. These
were randomly selected to represent a 10-year period (2004 to 2013) and
locations throughout the United Kingdom plus one isolate from Switzer-
land. Nine to 11 isolates per year were selected, with approximately equal
numbers of noninvasive and invasive strains. All GAS isolates were cul-
tured on Columbia horse blood agar (Oxoid, Basingstoke, United King-
dom) or in Todd-Hewitt liquid broth (Oxoid) at 37°C with 5% CO2.
Whole-genome sequencing and phylogenetic analysis. Multiplex
paired-end Illumina sequencing was performed on 34 isolates at Imperial
College London using Illumina MiSeq, generating 150-bp reads. The Il-
lumina MiSeq-generated short read sequences of strain H293 were used
with standard sequencing to generate a completed genome. Two indepen-
dent assemblies of the sequence reads were carried out using the SPAdes
assembler (43) (with k-mer sizes of 21, 33, and 55) and ABySS (44) (with
a k-mer size of 63). The resulting contig sequences were combined using
Zorro (http://www.lge.ibi.unicamp.br/zorro) and scaffolded against the
complete sequence of the M12 MGAS9429 genome (EMBL accession no.
CP000259) using ABACAS (Wellcome Trust Sanger Institute). Gap clo-
sure was carried out using the Gap5 program from the Staden package
(45), yielding an assembly consisting of 10 contigs in one scaffold. Contigs
were then joined by PCR and standard Sanger sequencing across gaps.
Automated annotation was performed on the completed genome using
Prokka (Victorian Bioinformatics Consortium [vicbioinformatics.com]),
and the resulting annotations were manually verified.
Using SMALT (Wellcome Trust Sanger Institute), reads weremapped
to the completed emm89 H293 genome (EMBL accession no. ERP002615
and HG316453.2), and single nucleotide polymorphisms (SNPs) were
identified. Concatenated SNPs identified in the core genome were used to
generate a maximum likelihood tree using RAXML (46). De novo assem-
bly sequences were constructed using Velvet and SPAdes. Regions of SNP
clustering and potential recombination were identified using Gubbins
(47).
Path-O-Gen (http://tree.bio.ed.ac.uk/software/pathogen/) was used
to conduct the linear regression of maximum likelihood root-to-tip dis-
tances against the year of sampling. TheBayesian software package BEAST
(v1.7.4) (48) was used to investigate the temporal dynamics of the emm89
population. To estimate the substitution rates and times for divergences
of internal nodes on the tree, a general time-reversible (GTR) model with
a gamma correction for among-site rate variation was used. To identify
themost suitablemodels, we compared the strict, lognormal-relaxed, and
exponential-relaxed molecular clock models and coalescent constant, ex-
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ponential growth, expansion growth, and Bayesian skyline tree models.
For each, three independent chains were run for 100 million generations,
with sampling every 10 generations. On completion, each model was
checked for convergence, both by checking that exponential sequence
scheme (ESS) values were greater than 200 for key parameters and by
checking that independent runs had converged on similar results.Models,
including exponential and expansion population, which failed to con-
verge so were discarded. Models were compared for their fit to the data
using Bayes factors based on the harmonic mean estimator as calculated
by the program Tracer v1.4 from the BEAST package. The constant tree
model along with the strict molecular clock to accommodate for rate
variation among lineages was preferred. A burn-in of 10million states was
removed from each of the three independent runs of this model before
combining the results from those runs with the logcombiner program
from the BEAST package. A maximum clade credibility (MCC) tree was
created from the resulting combined trees using the treeAnnotator pro-
gram, also from the BEAST package.
NADase.NADase activity was measured as previously described (25).
Briefly, overnight bacterial culture supernatant was serially diluted 2-fold
in phosphate-buffered saline (PBS) and incubated with 0.67 mmol/liter
NAD (Sigma-Aldrich, Dorset, United Kingdom) for 1 h at 37°C. Reac-
tion mixtures were developed with 2 N NaOH and incubated in the dark
for 1 h before being visualized at 360 nm. Activity was measured as the
highest dilution capable of hydrolyzing NAD. Where required, bacterial
supernatant was also concentrated 10-fold with trichloroacetic acid
(TCA)-acetone precipitation and then subjected to Western blotting and
probed for NADase with rabbit anti-NADase (Abcam, Cambridge,
United Kingdom).
SLO activity. SLO activity was measured as previously described (25).
Briefly, GAS strains were cultured to an A600 of 0.25, and filtered culture
supernatant was incubated with 20 mmol/liter dithiothreitol (DTT) for
10 min at room temperature. Two percent sheep erythrocytes suspended
in PBS was added and incubated at 37°C for 30 min before centrifugation
at 3,000  g for 5 min. Supernatants were then transferred to a 96-well
plate, and A541 was read. As a control, 20 g of water-soluble cholesterol
(Sigma-Aldrich)was added as a specific inhibitor of SLO. SLO activity was
reported as that specific to SLO (A541 of the sample minus A541 in the
presence of cholesterol) expressed as a percentage of the positive control
(sheep erythrocytes incubated with H2O).
Capsule assay.GAS strains were streaked onto Columbia horse blood
agar from frozen glycerol stocks and incubated overnight at 37°C and 5%
CO2. Colonies (5 to 10) were then taken off the plates and suspended in
300 l sterile 10 mM Tris, pH 7.5. An aliquot of this suspension was then
serially diluted and plated to obtain the number of CFU. Hyaluronic acid
capsule was then detected and quantified as previously described (26).
Growth in whole human blood. Growth in whole human blood was
performed as previously described (49). Briefly, approximately 50 CFU of
GAS was inoculated into 300 l of freshly extracted heparinized human
blood and incubated at 37°C for 3 hours with rotation. Final CFU were
measured by plating onto blood agar. The multiplication factor was cal-
culated by dividing the final CFU by the initial inoculum.
Bacterial adhesion assay.Bacterial adhesion assayswere performed as
previously described (50, 51) with minor modifications. Bacterial strains
were cultured overnight before being diluted 1 in 100 in fresh Todd-
Hewitt medium (Oxoid), and 100 l was applied to uncoated 96-well
polystyrene tissue culture plates and incubated at 37°C for 24 h. Plates
were then washed three times in PBS and stained with 100 l Gram’s
crystal violet for 30min. After extensive washing, the stain was solubilized
in 100% ethanol and A595 was measured.
Nucleotide sequence accession numbers. The sequences of the 34
isolates subjected to multiplex paired-end Illumina MiSeq sequencing
were deposited in the short read archive (EMBL accession no.
ERP005815).WGS data from the additional 97 emm89 isolates sequenced
using IlluminaHiSeqwere also deposited in the short read archive (EMBL
accession numbers ERR485686 to ERR485692, ERR485694 to
ERR485700, ERR485702 to ERR485777, ERR485823 to ERR485825,
ERR485827, ERR485871, and ERR485872). The completed emm89 H293
genome was deposited under EMBL accession no. ERP002615 (SRA) and
HG316453.2.
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